Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016; 388: 1281–1290.

Published: 30th November 2016

Authors: Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC et al.


In this multicentre study, 212 patients with chronic refractory fistulas were randomized. The active treatment was associated with a better chance of remission at six months: 50 per cent versus 34 per cent with placebo, P=0.024.

Pubmed Link

Your comments